sglt2 inhibitors vs glp 1 Comparative effectiveness of inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records Hypoglycemia Risk With SGLT2 Inhibitors

Until NHANES next reporting, the answer is obesity rates = zero change, severe obesity still rising

When fat pads that normally provide volume and support to areas like the mons pubis and labia majora diminish quickly, it can cause the skin and surrounding tissues to appear looser or saggy

[20] [21] Many pharmacies and healthcare facilities offer medication take-back programs

Guided GLP-1 Weight Loss Your results matter, but so does how you feel along the way

A 20% relative risk reduction in MACE, including myocardial infarction, stroke, and cardiovascular death and a 30% relative risk reduction in hospitalizations for HF ( The VERTIS trial, involving 8246 patients with T2DM, compared ertugliflozin 5 mg or 15 mg daily to placebo for 3.5 years